Market Closed -
Other stock markets
|
Pre-market 06:32:01 | |||
741.3 EUR | +2.62% | 740.3 | -0.13% |
06:42am | Eli Lilly Reports Positive Trial Results for Crohn's Disease Treatment | MT |
06:27am | China Grants Green Light to Eli Lilly's Diabetes Treatment | MT |
Evolution of the average Target Price on Eli Lilly and Company
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Eli Lilly and Company
Argus | |
Redburn Atlantic | |
China International Capital | |
JPMorgan Chase | |
Wolfe Research | |
Barclays | |
BMO Capital | |
Leerink Partners | |
Deutsche Bank Securities | |
Truist Securities | |
Goldman Sachs | |
Wells Fargo Securities | |
Morgan Stanley | |
Jefferies & Co. | |
UBS | |
BofA Securities | |
DZ Bank | |
JEFFERIES | Akash Tewari |
Cantor Fitzgerald | |
Morningstar | |
Guggenheim | |
Daiwa Securities | |
Berenberg Bank | |
Citigroup | |
Credit Suisse | |
HSBC | |
TD Cowen | |
SVB Securities LLC | |
Cowen | |
Mizuho Securities |
EPS Revisions
- Stock Market
- Equities
- LLY Stock
- LLY Stock
- Consensus Eli Lilly and Company